Tuesday, March 5, 2024
Financial News Conference on the Full Year 2023 Results
Bayer aims to enhance performance and regain strategic flexibility by 2026 – adjusted guidance for 2023 achieved
- Anderson: Bayer to strengthen Pharmaceuticals pipeline, address litigation, reduce debt and radically overhaul operating model
- Dynamic Shared Ownership to deliver growth through customer centricity and innovation speed as well as annual savings of two billion euros from 2026
- Structural changes remain an option, but “not now”
- Fiscal 2023: Group sales at 47.637 billion euros (Fx & portfolio adj. minus 1.2 percent), currency headwinds of around 2 billion euros
- EBITDA before special items falls to 11.706 billion euros (minus 13.4 percent)
- Core earnings per share at 6.39 euros (minus 19.5 percent)
- Free cash flow at 1.311 billion euros, net financial debt rises to 34.498 billion euros
- Outlook for 2024: sales roughly level year on year (Fx & portfolio adj.), currency-adjusted EBITDA before special items and core earnings per share to decline